As of 2026-03-17, the Relative Valuation of Atea Pharmaceuticals Inc (AVIR) is (38.31) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.05 USD, the upside of Atea Pharmaceuticals Inc based on Relative Valuation is -733.1%.
The range of the Relative Valuation is (37.29) - (40.37) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.4x - 20.0x | 19.1x |
| Forward P/E multiples | 17.0x - 19.9x | 18.7x |
| Fair Price | (37.29) - (40.37) | (38.31) |
| Upside | -716.4% - -767.3% | -733.1% |
| Date | P/E |
| 2026-03-17 | -2.98 |
| 2026-03-16 | -2.99 |
| 2026-03-13 | -3.01 |
| 2026-03-12 | -3.01 |
| 2026-03-11 | -3.01 |
| 2026-03-10 | -2.99 |
| 2026-03-09 | -3.03 |
| 2026-03-06 | -2.91 |
| 2026-03-05 | -2.62 |
| 2026-03-04 | -2.46 |
| 2026-03-03 | -2.38 |
| 2026-03-02 | -2.40 |
| 2026-02-27 | -2.31 |
| 2026-02-26 | -2.31 |
| 2026-02-25 | -2.28 |
| 2026-02-24 | -2.29 |
| 2026-02-23 | -2.26 |
| 2026-02-20 | -2.29 |
| 2026-02-19 | -2.34 |
| 2026-02-18 | -2.27 |
| 2026-02-17 | -2.27 |
| 2026-02-13 | -2.13 |
| 2026-02-12 | -2.14 |
| 2026-02-11 | -2.20 |
| 2026-02-10 | -2.05 |
| 2026-02-09 | -2.04 |
| 2026-02-06 | -2.05 |
| 2026-02-05 | -1.98 |
| 2026-02-04 | -2.02 |
| 2026-02-03 | -2.01 |
| 2026-02-02 | -2.01 |
| 2026-01-30 | -2.09 |
| 2026-01-29 | -1.93 |
| 2026-01-28 | -1.91 |
| 2026-01-27 | -2.01 |
| 2026-01-26 | -1.97 |
| 2026-01-23 | -2.03 |
| 2026-01-22 | -1.80 |
| 2026-01-21 | -1.74 |
| 2026-01-20 | -1.70 |
| 2026-01-16 | -1.68 |
| 2026-01-15 | -1.70 |
| 2026-01-14 | -1.75 |
| 2026-01-13 | -1.73 |
| 2026-01-12 | -1.78 |
| 2026-01-09 | -1.70 |
| 2026-01-08 | -1.78 |
| 2026-01-07 | -1.72 |
| 2026-01-06 | -1.68 |
| 2026-01-05 | -1.68 |